Adenoid cystic carcinoma of the lacrimal gland: Role of nuclear survivin (BIRC5) as a prognostic marker

Histopathology

Volumn 62, Issue 6, 2013, Pages 840-846

  Mulay, Kaustubh ^a   Puthyapurayil, Fairooz M ^a   Mohammad, Javed Ali ^a   Hasnat Ali, Mohammad ^a   Honavar, Santosh G ^a   Reddy, Vijay Anand P ^a  

^a L V PRASAD EYE INSTITUTE   (India)

Author keywords

Adenoid cystic carcinoma; Lacrimal gland; Survivin (BIRC5)

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; SURVIVIN;

ADENOID CYSTIC CARCINOMA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHILD; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACRIMAL GLAND; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; APOPTOSIS; CARCINOMA, ADENOID CYSTIC; CELL NUCLEUS; CELL PROLIFERATION; CHILD; DISEASE-FREE SURVIVAL; EYE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; LACRIMAL APPARATUS DISEASES; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84876797176     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12073     Document Type: Article

References (48)

1. Goder GJ. Tumours of lacrimal gland. Orbit 1982; 12; 91-96.
2. Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1. Ophthalmology 2004; 111; 997-1008.
3. Santos RR, Damasceno RW, de Pontes FS et al. Ten-year follow-up of a case series of primary epithelial neoplasms of the lacrimal gland: clinical features, surgical treatment and histopathological findings. Arq. Bras. Oftalmol. 2010; 73; 33-39.
4. Reese AB. Expanding lesions of the orbit. Trans. Ophthalmol. Soc. UK 1971; 91; 85-104.
5. Henderson JW. Orbital tumours. 3rd ed. New York: Raven Press, 1994; 323-342.
6. Shinder R, Al-Zubidi N, Esmaeli B. Survey of orbital tumors at a comprehensive cancer center in the United States. Head Neck 2011; 33; 610-614.
7. Khan AJ, DiGiovanna MP, Ross DA et al. Adenoid cystic carcinoma: a retrospective clinical review. Int. J. Cancer 2001; 96; 149-158.
8. Spiro RH, Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am. J. Surg. 1992; 164; 623-628.
9. Le Qt, Birdwell S, Terris DJ et al. Post operative irradiation of minor salivary gland malignancies of the head and neck. Radiother. Oncol. 1999; 52; 165-171.
10. Prokopakis EP, Snyderman CH, Hanna EY, Carrau RL, Jhonson JT, D'Amico F. Risk factors for local recurrence of adenoid cystic carcinoma: the role of post operative radiation therapy. Am. J. Otolaryngol. 1999; 20; 281-286.
11. Garden AS, Weber RS, Morrison WH et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int. J. Radiat. Oncol. Biol. Phys. 1995; 32; 619-626.
12. Ko YH, Roh SY, Won HS et al. Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck. Head Neck Oncol. 2010; 2; 30-38.
13. Le Tourneau C, Razak AR, Levy C et al. Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland. Br. J. Ophthalmol. 2011; 95; 1483-1489.
14. Costa AF, Altemani A, Vékony H et al. Genetic profile of adenoid cystic carcinomas with high-grade transformation versus solid type. Cell Oncol. 2011; 34; 369-379.
15. Falbo V, Floridia G, Censi F, Marra M, Foschini MP, Taruscio D. Three cases of rare salivary gland tumours: a molecular study of TP53, CDKN2A/ARF, RAS, BRAF, PTEN, MAPK2 and EGFR genes. Oncol. Rep. 2011; 26; 3-11.
16. Seethala RR, Cieply K, Barnes EL, Dacic S. Progressive genetic alterations of adenoid cystic carcinoma with high-grade transformation. Arch. Pathol. Lab. Med. 2011; 135; 123-130.
17. Al-Rawi NH, Omer H, Al Kawas S. Immunohistochemical analysis of p53 and bcl-2 in benign and malignant salivary glands tumors. J. Oral Pathol. Med. 2010; 39; 48-55.
18. de Lima MD, Marques YM, Alves SM Jr et al. MDM2, P53, P21WAF1 and pAKT protein levels in genesis and behaviour of adenoid cystic carcinoma. Cancer Epidemiol. 2009; 33; 142-146.
19. Yamazaki M, Fujii S, Murata Y, Hayashi R, Ochiai A. High expression level of geminin predicts a poor clinical outcome in salivary gland carcinomas. Histopathology 2010; 56; 883-892.
20. Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008; 53; 567-577.
21. Suzzi MV, Alessi A, Bertarelli C et al. Prognostic relevance of cell proliferation in major salivary gland carcinomas. Acta Otorhinolaryngol. Ital. 2005; 25; 161-168.
22. Marques YM, Giudice FS, Freitas VM et al. Oestrogen receptor β in adenoid cystic carcinoma of salivary glands. Histopathology 2012; 60; 609-616.
23. Dori S, Trougouboff P, David R, Buchner A. Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin. Oral Oncol. 2000; 36; 450-453.
24. Defaud-Hénon F, Tunon-de-Lara C, Fournier M et al. Adenoid cystic carcinoma of the breast: clinical, histological and immunohistochemical characterization. Ann. Pathol. 2010; 30; 7-16.
25. Marioni G, Agostini M, Bedin C et al. Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants. Histopathology 2012; 61; 247-256.
26. Hui MK, Lai KK, Chan KW et al. Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma. Med. Oncol. 2012; 29; 3009-3016.
27. Adamkov M, Kajo K, Vybohova D. Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma. Neoplasm 2012; 59; 30-37.
28. Ekeblad S, Lejonklou MH, Stålberg P, Skogsied B. Prognostic relevance of survivin in pancreatic endocrine tumors. World J. Surg. 2012; 36; 1411-1418.
29. Wright JE, Rose GE, Garner A. Primary malignant neoplasms of the lacrimal gland. Br. J. Ophthalmol. 1992; 76; 401-407.
30. Tellado MV, McLean IW, Specht CS, Varga J. Adenoid cystic carcinomas of the lacrimal gland in childhood and adolescence. Ophthalmology 1997; 104; 1622-1625.
31. Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE. Adenoid cystic carcinoma of the head and neck - a 20 years experience. Int. J. Oral Maxillofac. Surg. 2004; 33; 25-31.
32. Da Cruz Perez DE, de Abreu Alves F, Nobuku Nishimoto I, de Almeida OP, Kowalski LP. Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncol. 2006; 42; 139-146.
33. Hamper K, Lazar F, Dietel M et al. Prognostic factors for adenoid cystic carcinoma of the head and neck: a retrospective evaluation of 96 cases. J. Oral Pathol. Med. 1990; 19; 101-107.
34. Jaso J, Malhotra R. Adenoid cystic carcinoma. Arch. Pathol. Lab. Med. 2011; 135; 511-515.
35. Fordice J, Kershaw C, El-Naggar A, Goepfert H. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch. Otolaryngol. Head Neck Surg. 1999; 125; 149-152.
36. Seethala RR. Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv. Anat. Pathol. 2011; 18; 29-45.
37. Zushi Y, Noguchi K, Hashitani S et al. Relations among expression of CXCR4, histological patterns, and metastatic potential in adenoid cystic carcinoma of the head and neck. Int. J. Oncol. 2008; 33; 1133-1139.
38. Wiseman SM, Popat SR, Rigual NR et al. Adenoid cystic carcinomas of the paranasal sinuses or nasal cavity: a 40 year review of 35 cases. Ear Nose Throat J. 2002; 81; 510-514.
39. Matsuba HM, Thawley SE, Simpson JR, Levine LA, Mauney M. Adenoid cystic carcinoma of major and minor salivary gland origin. Laryngoscope 1984; 94; 1316-1318.
40. Altieri DC. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J. Biol. Chem. 1994; 269; 3139-3142.
41. Kuo P-C, Lui H-F, Chao J-I. Survivin and p53 modulate Quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J. Biol. Chem. 2004; 279; 55875-55885.
42. Caldas H, Jiang Y, Holloway MP et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005; 24; 1994-2007.
43. Noton EA, Colnaghi R, Tate S et al. Molecular analysis of survivin isoforms. Evidence that alternatively spliced variants do not play a role in mitosis. J. Biol. Chem. 2006; 281; 1286-12895.
44. Mahotka C, Liebmann J, Wenzel M et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 2002; 9; 1334-1342.
45. Krieg A, Mahotka C, Krieg T et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br. J. Cancer 2002; 86; 737-743.
46. Li F. Role of survivin and its splice variants in tumorigenesis. Br. J. Cancer 2005; 92; 212-216.
47. Ponnelle T, Chapusot C, Martin L et al. Cellular localization of survivin: impact on the prognosis in colorectal cancer. J. Cancer Res. Clin. Oncol. 2005; 131; 504-510.
48. Liao Y, Zeng H, Wang X et al. Expression patterns and prognostic significance of inhibitor of apoptosis proteins in adenoid cystic carcinoma and pleomorphic adenoma of the lachrymal gland. Exp. Eye Res. 2009; 88; 4-11.